Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2025-523346-27-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-523346-27-00
Registry
EU Clinical Trials Information System
CTIS number
2025-523346-27-00
Asset
psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico)
Sponsor, as registered
Universita' Degli Studi G. D'Annunzio Di Chieti
Phase
Therapeutic exploratory (Phase II)
Indication
Treatment-Resistant Depression
Status
Authorised
Start date
15/08/2026
Primary completion
CTIS does not publish one.
Member states concerned
Italy
Sites
1

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-09-08

Notes on the record

Decision date 2026-08-14, record published 2026-08-17. totalNumberEnrolled 30. First submission (suffix -00). No ClinicalTrials.gov record found 2026-09-08; the only psilocybin plus trazodone NCT (NCT07210112) is the Paris Sainte-Anne trial. Read from the CTIS public API. countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded in this table; see data/decisions.csv.

Company

Through psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico): University of Chieti-Pescara

Cited in

Issues quoting 2025-523346-27-00 in their own text.